Adjuvant chemotherapy for resected stage-ia lung adenocarcinoma with micropapillary histologic pattern

Clicks: 59
ID: 316937
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #1 of 150 articles by views in Interdisciplinary CardioVascular and Thoracic Surgery

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 150 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
OBJECTIVES: The micropapillary pattern is a high-risk factor for postoperative recurrence in lung adenocarcinoma (LUAD), but the role of adjuvant chemotherapy (ACT) in stage IA LUAD with micropapillary pattern (LUADmp) after resection remains unclear. METHODS: From September 2017 to August 2020, in the phase II trial, resected stage IA LUADmp patients received ACT (pemetrexed and carboplatin), forming the ACT-group. While those meeting the trial criteria but declining ACT in the same period were designated as the SoC-group. Recurrence-free survival (RFS) was compared between groups using univariate and multivariate analyses. RESULTS: The number of patients in ACT-group and SoC-group was 81 and 75, respectively. Compared to SoC-group, patients in ACT-group were younger (60.0 years vs 64.0 years, p = 0.019), had a lower proportion of EGFR/ALK mutation (58.0% vs 78.7%, p = 0.006), and had a higher proportion of Spread Through Air Spaces (59.3% vs 40.0%, p = 0.016). At the cut-off date of January 31st 2025, the median duration of follow-up was 65.6 months. Five-year RFS in ACT-group met the prespecified primary end-point, and no significant difference was observed between ACT-group and SoC-group (ACT-group vs SoC-group: 88.9% vs 86.7%, log-rank p = 0.534). Multivariate analysis showed ACT could not predict RFS independently (HR, 0.865, 95% CI, 0.334-2.240, p = 0.765). CONCLUSIONS: ACT was not significantly associated with improved RFS for stage IA LUADmp patients postoperatively. This study was registered at ClinicalTrials.gov: NCT03351842.
Reference Key
openalex_W7164181366 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors
Journal Interdisciplinary CardioVascular and Thoracic Surgery
Year 2026
DOI
10.1093/icvts/ivag165
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.